about
Advances in pancreatic cancer research: moving towards early detectionMolecular therapeutics in pancreas cancerFrom bench to bedside a comprehensive review of pancreatic cancer immunotherapy.The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsViro-immune therapy: A new strategy for treatment of pancreatic cancerCancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionPerspectives in the treatment of pancreatic adenocarcinomaIncreased Oxidative Stress as a Selective Anticancer TherapyPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesNeural Regulation of Pancreatic Cancer: A Novel Target for InterventionOrchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not DestructionRole of bacterial infections in pancreatic cancerFluorescent imaging of cancerous tissues for targeted surgery.Ion channels and transporters in tumour cell migration and invasionHeterogeneity and targeting of pancreatic cancer stem cellsGenetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencingDefining normoxia, physoxia and hypoxia in tumours-implications for treatment responseOncolytic viral therapy for pancreatic cancer: current research and future directionsThe Key Role of Calmodulin in KRAS-Driven AdenocarcinomasHuman correlates of provocative questions in pancreatic pathologySIBLINGs and SPARC families: their emerging roles in pancreatic cancerThe use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer.Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic CancerThe P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.SOX9 inhibits β-TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated MacrophagesApplication of glycoscience to the early detection of pancreatic cancerTargeting microenvironment in cancer therapeuticsFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerTargeting tumor-associated macrophages to combat pancreatic cancerApplication of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance modelPredictive modeling of in vivo response to gemcitabine in pancreatic cancerLong-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In VitroSoluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxificationTumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolismBeyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.Pancreatic stellate cells promote hapto-migration of cancer cells through collagen I-mediated signalling pathway.Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.A mathematical model for pancreatic cancer growth and treatmentsRe-adapting T cells for cancer therapy: from mouse models to clinical trials.
P2860
Q24563998-C25C8341-07B0-4FC5-97F1-9052C518368DQ26751709-B6B8A74E-FB81-48C6-BD57-152E08F402CCQ26765123-2C174B44-5C8F-4525-B3F7-712028AF8BA4Q26765247-4551D8F9-68EC-4D99-9D42-1231ED611B37Q26774641-1D45F0F6-1D62-4B91-AB98-C3488F5F7177Q26777542-86B3F695-7250-4BE2-89B7-02A353667E2CQ26797248-BD7BBF07-94E0-4666-81BB-D44E1748F2CCQ26798210-05763895-2A2A-4D94-878A-1F4558DA19F6Q26799714-F43A632D-7AB3-4F00-B43A-6BEA64E651CBQ26801748-94A7177D-1D33-4196-B831-D1C6A8C1421CQ26801834-CE6C2212-93B4-48FA-8ADD-4FF4E89FA99EQ26823764-2073DE1A-C95A-4578-BA3C-FD94887DEC0EQ26830905-0E8246AC-7CFF-4339-8CE3-0A1E1292AB0CQ26849490-C4792FFB-7734-47C0-BC2C-32AB05C7D046Q26851734-ECF17D29-4F83-4423-B1AC-5E8A0B86126BQ26991615-44AA0313-7CC2-42CC-AAC7-614CC07F0C42Q27009437-28B7DC3D-DD0F-4C67-AB7F-F67C1EC578FCQ27011439-538BA4F3-2856-43A9-996E-69BB37076C80Q27021883-5ACE4FB3-D3F7-4406-AD83-8F89CC48D3DAQ27023576-0F221F82-49C7-4A08-9286-2602955C5BA0Q27027759-81D303A2-6B46-479E-AC2E-121B599BA352Q27300759-8BD3CD6C-F26D-4BAE-99CF-B3D55CAEE0D6Q27300789-198E7628-25A8-47D5-91DF-2C736306BE6CQ27304392-0E0D9BC2-6A30-4DD5-BFB3-2DE3BC0B25D4Q27341897-8A449D8C-F772-44F0-A635-11601590B21FQ27348974-BDF86730-3E5C-4D21-8002-C4E9216BDE8FQ28066814-7EA542CC-93A1-4076-AF78-E164F3DAAA28Q28067219-492F50E1-68B5-4769-A368-2F889693EEB4Q28075540-1A354E13-E82A-4519-AC9E-D8F109A26491Q28076103-3B4F1388-8AFA-4301-8778-D6144FCBFA2AQ28533194-1369E14F-13C0-4A00-A1FA-1F3DD64D6429Q28533633-13D664C6-34BD-4619-89CD-22E66CDF0777Q28554939-69F4C8FE-741E-47A3-A13E-C2293D3DC65DQ28822225-E3CEDF3A-012E-4089-B992-ADC9A6C124F5Q28834389-6E6701CA-6C7A-4EC5-ACF6-471DB82BB137Q30276874-D46EE2E9-17DA-4889-8A15-D24D6D022C6CQ30567121-12689D3B-A239-41F0-839E-D37CCF88C5D7Q30620697-99B5E8FC-2BD1-478A-8B7D-DA64DD1AA8B9Q33571981-01347D9B-FB42-4A07-9F4B-2C6B37DE7839Q33588711-AA846E20-A409-4A75-8680-E4B05DEEA05E
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
The pancreas cancer microenvironment
@ast
The pancreas cancer microenvironment
@en
The pancreas cancer microenvironment
@nl
type
label
The pancreas cancer microenvironment
@ast
The pancreas cancer microenvironment
@en
The pancreas cancer microenvironment
@nl
prefLabel
The pancreas cancer microenvironment
@ast
The pancreas cancer microenvironment
@en
The pancreas cancer microenvironment
@nl
P2093
P2860
P3181
P1476
The pancreas cancer microenvironment
@en
P2093
A. Gopinathan
D. A. Tuveson
D. S. Chan
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-11-3114
P407
P577
2012-08-15T00:00:00Z